Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Items 401–500 of 999
Gorwood, P. A. P. M., Bayle, F., Vaïva, G., Courtet, P., Corruble, E., & Llorca, P. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2012.11.004 · Cited by 31
“However, the same study showed that a similar proportion of nonresponders could benefit from a switch to a different class of antidepressant or addition of a second treatment and thus achieve remission [42].”
BackgroundTreatment of sleep dysfunction and psychiatric disorders
Becker, P. M. (2006) · Current Treatment Options in Neurology · doi:10.1007/s11940-006-0026-6 · Cited by 39
Brignone, M., Diamand, F., Painchault, C., & Takyar, S. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1128404 · Cited by 30
Economic factors in of patients’ nonadherence to antidepressant treatment
Jeon‐Slaughter, H. (2012) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-012-0497-6 · Cited by 35
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc128 · Cited by 38
Self-citationHough, C. M., Lindqvist, D., Epel, E. S., Denis, M. S., Reus, V. I., Bersani, F. S., Rosser, R., Mahan, L., Burke, H. M., Wolkowitz, O. M., et al. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.11.035 · Cited by 32
Results of the STAR*D Study: Implications for Clinicians and Drug Developers
Preskorn, S. (2009) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000344918.51404.1e · Cited by 28
Optimizing the exercise prescription for depression: the search for biomarkers of response
Medina, J. L., Jacquart, J., & Smits, J. A. (2015) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2015.02.003 · Cited by 30
“Toups and Trivedi [1] discussed the need to identify characteristics for antidepressant medication matching as only a little over a third of patients seeking antidepressant medication treatment achieve remission with their first two treatment steps, and nearly a third of all patients only achieve minimal or no improve…”
BackgroundContinuing care in the treatment of addictive disorders
McKay, J. R. (2006) · Current Psychiatry Reports · doi:10.1007/s11920-006-0036-9 · Cited by 32
Lam, R. W. (2007) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000277959.60604.d1 · Cited by 30
“Large-scale clinical trials such as STAR*D have shown that over one-third of patients do not achieve remission, even after four sequential treatments that include SSRIs, SNRIs, and combination/augmentation strategies (Rush et al., 2006b).”
BackgroundPandina, G. J., PhD, Canuso, C. M., MD, Turkoz, I., MS, Kujawa, M., MD, PhD, Mahmoud, R. A., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4108 · Cited by 30
Keks, N. A., Burrows, G. D., Copolov, D., Newton, R., Paoletti, N., Schweitzer, I., & Tiller, J. W. G. (2007) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb00838.x · Cited by 31
Emerging treatments for depression
Holtzheimer, P. E., & Nemeroff, C. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.17.2323 · Cited by 32
“Although treatments for depression are often effective, up to 60 – 70% of patients continue to experience residual symptoms despite appropriate treatment [3,4], and 10 – 20% may show minimal or no response to multiple aggressive treatments, including electroconvulsive therapy (ECT) [5,6].”
BackgroundBerwian, I. M., Wenzel, J. G., Kuehn, L., Schnuerer, I., Kasper, L., Veer, I. M., Seifritz, E., Stephan, K. E., Walter, H., & Huys, Q. J. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-79170-9 · Cited by 29
“To this end, we examined (1) whether RSFC connectivity differs between remitted medicated patients and controls; (2) whether pre-discontinuation RSFC differs between patients who relapse after discontinuation and those who remain well; (3) the effects of discontinuation on RSFC; and (4) to what extent changes in RSFC…”
BackgroundRational site-directed pharmacotherapy for major depressive disorder
Blier, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000400 · Cited by 29
Schultz, J., & Joish, V. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.12.1604 · Cited by 29
Circuit based anti-correlation, attention orienting, and major depression
Fossati, P. (2019) · CNS Spectrums · doi:10.1017/s1092852918001402 · Cited by 31
Psychopharmacologic treatment of pediatric major depressive disorder
Boylan, K., Romero, S., & Birmaher, B. B. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0442-z · Cited by 33
“Switching within SSRI class may be effective in 50% of adults (Fleck and Horwath 2005); however, switching between class may be better in adults (Rush et al. 2006).”
Backgroundthe EMC Study Group, Tadić, A., Gorbulev, S., Dahmen, N., Hiemke, C., Braus, D. F., Röschke, J., van Calker, D., Wachtlin, D., Kronfeld, K., et al. (2010) · Trials · doi:10.1186/1745-6215-11-21 · Cited by 29
“The switch from escitalopram to venlafaxine led to a remission in 24% after 14 weeks of treatment [38]; for the treatment period of this trial (day 29-56), we assume a remission rate of 20% on day 56 for TAU 1.”
BackgroundAlgorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness
Bauer, M., Rush, A. J., Ricken, R., Pilhatsch, M., & Adli, M. (2018) · Pharmacopsychiatry · doi:10.1055/a-0643-4830 · Cited by 43
“Thus, they could opt out of CT but had to agree to the 3 switch treatments to continue in the study [26], or they could opt out of switch options, but they had to accept all of the medication augmentation options [27].”
BackgroundSelf-citationExercise as a treatment modality for depression: A narrative review
Al‐Qahtani, A. M., Shaikh, M. A. K., & Shaikh, I. A. (2018) · Alexandria Journal of Medicine · doi:10.1016/j.ajme.2018.05.004 · Cited by 36
“Most of the patients on antidepressant medications do not achieve remission after initial treatment(15) and nearly one-third of the patients do not achieve remission even after several treatment steps.(16,17) The patients with”
BackgroundAssociation between depression subtypes and response to repeated‐dose intravenous ketamine
Wang, C., Zhou, Y., Zheng, W., Liu, W., Zhan, Y., Li, H., Chen, L., Zhang, B., Walter, M., Li, M., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13096 · Cited by 35
Pharmacotherapy for Treatment-Resistant Depression
Vas, C., Jain, A., Trivedi, M., Jha, M. K., & Mathew, S. J. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.012 · Cited by 32
Self-citationWang, Z., Zhang, Q., Huang, H., & Liu, Z. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.158 · Cited by 33
Schmitt, A. B., Bauer, M., Volz, H., Mœller, H., Jiang, Q. L., Ninan, P. T., & Loeschmann, P.-A. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0003-7 · Cited by 29
“This assumption is supported by data from large databases [33], non-interventional studies [29] and clinical trials in treatment resistant depression (including patients after failure of previous treatment, mainly SSRI therapy) [4, 45 , 53].”
MethodHoner, W. G., Thornton, A. E., Sherwood, M., MacEwan, G. W., Ehmann, T. S., Williams, R., Kopala, L. C., Procyshyn, R. M., & Barr, A. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721090-00001 · Cited by 31
Rosso, G., Rigardetto, S., Bogetto, F., & Maina, G. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.07.026 · Cited by 28
“However, the lower rates of response and remission of the STAR*D can be attributed to the inclusion of patients who were chronically depressed, had lower socioeconomic status and suffered from more comorbid somatic and psychiatric diseases (Rush et al., 2006).”
BackgroundInfluentialLeuchter, A. F., Cook, I. A., Hunter, A. M., & Korb, A. (2009) · Clinical EEG and Neuroscience · doi:10.1177/155005940904000207 · Cited by 29
Manoharan, A., Shewade, D. G., Rajkumar, R. P., & Adithan, C. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2099-9 · Cited by 29
“en as the first-line treatment for MDD owing to their relatively low toxicity and tolerability [3].”
Thase, M. E., Danchenko, N., Brignone, M., Florea, I., Diamand, F., Jacobsen, P. L., & Vieta, E. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.05.009 · Cited by 33
Self-citationDepression Outcomes of Spanish- and English-Speaking Hispanic Outpatients in STAR*D
Lesser, I., Zisook, S., Flores, D., Sciolla, A., Wisniewski, S., Cook, I., Epstein, M., Rosales, A., Gonzalez, C., Trivedi, M., et al. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.11.1273 · Cited by 27
Self-citationNoorafshan, A., Abdollahifar, M., Asadi-Golshan, R., Rashidiani-Rashidabadi, A., & Saied (2014) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2014-1971 · Cited by 29
“Selective serotonin reuptake inhibitors, including sertraline, are primarily used to treat major depression in adult patients (Rush et al. 2006).”
BackgroundPersonalized (N-of-1) Trials for Depression: A Systematic Review
Kronish, I. M., Hampsey, M., Falzon, L., Konrad, B., & Davidson, K. W. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000864 · Cited by 29
“Yet, studies show that up to 50% of patients who fail to respond to a first depression treatment can obtain benefit after switching to a second treatment.(10) This suggests that improving the selection of the initial depression treatment can greatly benefit patients suffering from depression.”
Efficacy of Exercise in Reducing Depressive Symptoms across 5-HTTLPR Genotypes
Rethorst, C. D., Landers, D. M., Nagoshi, C. T., & Ross, J. T. D. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181de7d51 · Cited by 33
“Despite the empirical evidence demonstrating the effectiveness of these treatments, response rates for antidepressants (37,46,47), psychotherapy (9), and ECT (35) indicate that a large number of individuals do not respond to these treatments.”
BackgroundN-Acetylcysteine Augmentation to Tranylcypromine in Treatment-Resistant Major Depression
Carvalho, A. F., Macêdo, D. S., Goulia, P., & Hyphantis, T. N. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31829839c6 · Cited by 27
Dogra, S., Kumar, A., Umrao, D., Sahasrabuddhe, A. A., & Yadav, P. N. (2016) · Scientific Reports · doi:10.1038/srep33401 · Cited by 27
“05) as well as Dynorphin A (1-13) (Supplementary Fig.”
BackgroundHow to choose an antidepressant medication
Bayes, A. J., & Parker, G. B. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13001 · Cited by 32
“If intolerability is the indication for AD switching, the STAR*D trial found that when the first SSRI was switched to a second, intolerance of one SSRI did not predict intolerance of the next (107).”
Tinklenberg, J. R., KRAEMER, H. C., Yaffe, K. S., Ross, L., Sheikh, J. I., Ashford, J. W., Yesavage, J. A., & Taylor, J. L. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3180986138 · Cited by 31
“In addition, some patients who fulfill all entry criteria for a RCT are unwilling to participate in a RCT where they may not receive active medications.(27) It is usually easier to enroll a more representative sample of patients into studies where they are assured of getting whatever treatment their individual physici…”
Lingeswaran, A. (2011) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.85393 · Cited by 32
“Deficiencies of existing treatments Antidepressant medication The Sequenced Treatment Alternatives to Relieve Depression trial,[18-23] which is a semi-naturalistic treatment algorithm designed to model as closely as possible the sequence of treatment options most commonly used in clinical practice, provides useful con…”
BackgroundAshby, C. R., Kehne, J. H., Bartoszyk, G. D., Renda, M. J., Athanasiou, M., Pierz, K. A., & Seyfried, C. A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.07.014 · Cited by 26
“Although only one 5-HT1A agonist (buspirone) is approved for the treatment of anxiety, several compounds with 5-HT1A agonist/partial agonist activity have been shown to augment response to other antidepressants (Blier and Ward, 2003; Charney, 1998; Gammans et al., 1992; Parsey et al., 2006; Robinson et al., 1990; Rush…”
BackgroundVortioxetine for the Treatment of Depression
Pearce, E. F., & Murphy, J. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014528305 · Cited by 29
“Attaining remission continues to be challenging, with patient remission rates of 25% to 35% with SSRIs, 25% to 57% with SNRIs, and 21% to 25% with bupropion in clinical trials.(7,10-12) The American Psychiatric Association guidelines for treating MDD recommend SSRIs, SNRIs, mirtazapine, and bupropion as first-line age…”
BackgroundHughes, M. C., Pradier, M. F., Ross, A. S., McCoy, T. H., Perlis, R. H., & Doshi‐Velez, F. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.5308 · Cited by 26
Psychiatric Disorder Criteria and their Application to Research in Different Racial Groups
Low, N. C. P., & Hardy, J. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-1 · Cited by 26
Depression and Anxiety in Late Life: Diagnostic Insights and Therapeutic Options
Kastenschmidt, E. K., & Kennedy, G. J. (2011) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20266 · Cited by 32
Prevalence and patterns of antidepressant switching amongst primary care patients in the UK
Mars, B., Heron, J., Gunnell, D., Martin, R. M., Thomas, K. H., & Kessler, D. S. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117693748 · Cited by 29
“Switching to another AD can improve remission rates; for example, in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, approximately one in four patients who did not respond/were intolerant to an initial selective serotonin reuptake inhibitor (SSRI) treatment achieved remission after switching…”
BackgroundResultInfluentialDual–Dual Action? Combining Venlafaxine and Mirtazapine in the Treatment of Depression
Malhi, G. S., Ng, F., & Berk, M. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701881587 · Cited by 26
Amsterdam, J. D., & Shults, J. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.07.007 · Cited by 29
Nikolin, S., Alonzo, A., Martin, D. M., Gálvez, V., Buten, S., Francis‐Taylor, R., Goldstein, J., Oxley, C. J., Hadži-Pavlović, D., & Loo, C. K. A. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz072 · Cited by 26
Fugger, G., Bartova, L., Fabbri, C., Fanelli, G., Dold, M., Swoboda, M. M. M., Kautzky, A., Zohar, J., Souery, D., Mendlewicz, J., et al. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01368-3 · Cited by 29
Whooley, M. A. (2012) · JAMA · doi:10.1001/jama.2012.3466 · Cited by 26
Pharmacokinetics and Efficacy of Fluvoxamine and Amitriptyline in Depression
Vezmar, S., Miljković, B., Vučićević, K. M., Timotijević, I., Prostran, M. S., Todorović, Z., & Pokrajac, M. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09013fp · Cited by 25
Hartung, D. M., Hamer, A. M., Middleton, L., Haxby, D. G., & Fagnan, L. J. (2012) · BMC Family Practice · doi:10.1186/1471-2296-13-129 · Cited by 28
“The initial module in this phase drew content heavily from the National Institutes of Mental Health-funded Sequenced Treatment Alternatives to Relieve Depression (STARD) trial [17].”
BackgroundResultSpotlight on Bupropion in Major Depressive Disorder???
Dhillon, S., Yang, L. P. H., & Curran, M. P. (2008) · CNS Drugs · doi:10.2165/00023210-200822070-00006 · Cited by 26
Review of treatment for late-life depression
Allan, C. L., & Ebmeier, K. P. (2013) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.112.010835 · Cited by 28
Antidepressant Switching Among Adherent Patients Treated for Depression
Marcus, S. C., Hassan, M., & Olfson, M. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.5.617 · Cited by 29
Cognitive Therapy and Interpersonal Psychotherapy: 30 Years Later
Weissman, M. M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.693 · Cited by 27
Lessons Learned From Psychotherapy Research
McKay, J. R. (2007) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00493.x · Cited by 27
Monden, R., Roest, A. M., van Ravenzwaaij, D., Wagenmakers, E., Morey, R. D., Wardenaar, K. J., & de Jonge, P. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.040 · Cited by 25
Dechantsreiter, E., Padberg, F., Morash, A., Kumpf, U., Nguyen, A., Menestrina, Z., Windel, F., Burkhardt, G., Goerigk, S. A., Morishita, T., et al. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01464-y · Cited by 30
Agomelatine: Efficacy at Each Phase of Antidepressant Treatment
Kennedy, S. H. (2009) · CNS Drugs · doi:10.2165/11318660-000000000-00000 · Cited by 29
Treatment with Antidepressant Medications in Private Health Plans
Larson, M. J., Miller, K., & Fleming, K. J. (2006) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-006-0088-5 · Cited by 24
“…health plans, employer groups, and Medicaid programs design utilization review programs or restrict formularies to contain costs, these procedures should target unexplained or off-label use and be careful to not reduce access to needed mental health care (Rush et al., 2006; Trivedi et al., 2006).”
BackgroundNoorafshan, A., Abdollahifar, M., Karbalay‐Doust, S., Asadi-Golshan, R., & Rashidiani-Rashidabadi, A. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.2.96 · Cited by 25
Zisook, S., Tal, I., Weingart, K. R., Hicks, P. B., Davis, L. L., Chen, P., Yoon, J., Johnson, G. R., Vertrees, J. E., Rao, S. D., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.07.023 · Cited by 25
Fabbri, C., Crisafulli, C., Calati, R., Albani, D., Forloni, G., Calabrò, M., Martines, R., Kasper, S. F., Zohar, J., Juven‐Wetzler, A., et al. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0766-1 · Cited by 26
Gałecki, P., & Bliźniewska-Kowalska, K. M. (2019) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/115208 · Cited by 30
Bobo, W. V., & Shelton, R. C. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903130609 · Cited by 25
“Remission rates fell progressively with completion of each successive stage (25% in stage 2, 18% in stage 3, 10% in stage 4) [15,17,18,73-75].”
BackgroundStrategic use of new generation antidepressants for depression: SUN(^_^)D study protocol
Furukawa, T. A., Akechi, T., Shimodera, S., Yamada, M., Miki, K., Watanabe, N., Inagaki, M., & Yonemoto, N. (2011) · Trials · doi:10.1186/1745-6215-12-116 · Cited by 23
“For example, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D), which was funded by the NIMH and cost approximately 3 million dollars, examined five switching strategies and four augmentation strategies among the patients who had not achieved remission to the 1 line SSRI treatment but was unable to c…”
MethodSoares, C. N., Fayyad, R. S., & Guico‐Pabia, C. J. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000049 · Cited by 24
“During the second STAR*D treatment step, 21% of patients who switched drugs and 30% of patients who had treatment augmented subsequently achieved remission.(9,10) Defining the best timing for changes remains a critical issue for physicians assessing their patients’ response to treatment: how long should a patient cont…”
BackgroundKim, E. Y., Ahn, H., Lee, M. Y., Yu, J., Yeom, J., Jeong, H., Min, H., Lee, H. J., Kim, K., & Ahn, Y. M. (2020) · Biomedicines · doi:10.3390/biomedicines8110455 · Cited by 25
“After unsuccessful treatment for MDD patients with a SSRI, the choice of a second drug is important for remission [5].”
MethodA review of quetiapine in combination with antidepressant therapy in patients with depression
Daly, E., & Trivedi, M. H. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1862 · Cited by 29
Esposito, D., Wahl, P. M., Daniel, G. W., Stoto, M. A., Erder, M. H., & Croghan, T. W. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.03.012 · Cited by 24
Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy
Lieberman, D. Z., & Massey, S. H. (2009) · Core evidence · doi:10.2147/ce.s5998 · Cited by 29
“in which patients who did not experience remission after 14 weeks of citalopram were randomized to a second SSRI (sertraline), bupropion (a medication with norepinephrine and dopamine activity), or venlafaxine.(75) A total of 727 subjects were enrolled in this study, and no statistically significant differences were f…”
Romera, I., Pérez, V., Menchón, J. M., Schacht, A., Papen, R., Neuhauser, D., Abbar, M., Picard, H., & Gilaberte, I. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.024 · Cited by 24
Narp Mediates Antidepressant-Like Effects of Electroconvulsive Seizures
Chang, A. D., Vaidya, P., Retzbach, E. P., Chung, S. J., Kim, U., Baselice, K. A., Maynard, K. R., Stepanian, A., Staley, M., Xiao, L., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.252 · Cited by 24
Keks, N. A., Burrows, G. D., Copolov, D., Newton, R., Paoletti, N., Schweitzer, I., & Tiller, J. W. G. (2007) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01194.x · Cited by 23
Treatment Strategies after SSRI Failure — Good News and Bad News
Rubinow, D. R. (2006) · New England Journal of Medicine · doi:10.1056/nejme068029 · Cited by 23
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
Freudenberg, F., Reif-Leonhard, C., Dawson, G. R., McKernan, R. M., & Reif, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107918 · Cited by 23
Management of major depressive disorder
Tordrup, D., & Cuijpers, P. J. (2014) · VU Research Portal · Cited by 22
Aldosary, F., Norris, S., Tremblay, P., James, J. S., Ritchie, J., & Blier, P. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab086 · Cited by 25
Lam, R. W., Lönn, S. L., & Despiégel, N. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833948d8 · Cited by 22
“Unauthorized reproduction of this article is prohibited. another SSRI (sertraline) or to non-SSRI agents (bupropion-SR or venlafaxine-XR) (Rush et al., 2006).”
BackgroundNoorafshan, A., Abdollahifar, M., Karbalay‐Doust, S., Asadi-Golshan, R., & Rashidiani-Rashidabadi, A. (2015) · Folia Neuropathologica · doi:10.5114/fn.2015.49976 · Cited by 22
Mohamed, S., Johnson, G. R., Vertrees, J. E., Guarino, P., Weingart, K. R., Young, I. T., Yoon, J., Gleason, T., Kirkwood, K. A., Kilbourne, A. M., et al. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.08.005 · Cited by 23
Good, better, best: clinical scenarios for the use of L-methylfolate in patients with MDD
Jain, R., Manning, S., & Cutler, A. J. (2019) · CNS Spectrums · doi:10.1017/s1092852919001469 · Cited by 25
“Of the patients who received secondary treatments after failure of initial SSRI therapy, 18%, 21%, and 25% achieved remission with sertraline, sustained-release bupropion, and extended-release venlafaxine treatment, respectively.(17) Only 10% to 16% achieved remission in their third phase of treatment.”
(2017) · Europe PMC (PubMed Central) · Cited by 33
Pharmacogenetics of SSRIs and Sexual Dysfunction
Osis, L., & Bishop, J. R. (2010) · Pharmaceuticals · doi:10.3390/ph3123614 · Cited by 23
“STAR*D is the largest effectiveness trial of antidepressant treatment to date [4] and is providing important insight into treatment response profiles in a large “real world” study sample of subjects with MDD.”
BackgroundWang, Y., Wei, J., Chen, T., Yang, X., Zhao, L., Wang, M., Dou, Y., Du, Y., Ni, R., Li, T., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.907034 · Cited by 24
“Identification of miRNAs Reads obtained from the sequencing machines were filtered to generate clean reads according to the following rules: (1) removing reads without 3 adapters; (2) removing reads containing 5 adapters; (3) removing low-quality reads containing more than one low-quality (Q value ≤ 30) base or contai…”
BackgroundMethodPeng, Y., Huang, Y., Chen, B., He, M., Jiang, L., Li, Y., Huang, X., Pei, C., Zhang, S., Li, C., et al. (2022) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2022.3203073 · Cited by 22
“one treatment, up to one-half, attain a benefit after changing 70 to another medicine [12].”
BackgroundHan, Q.-Q., Wu, P., Li, Y., Cao, Y., Chen, J., & Wang, F. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102543 · Cited by 23
Pharmacological Treatment of Unipolar Depression
Anderson, I. M. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_208 · Cited by 21
Bobo, W. V., & Shelton, R. C. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.44 · Cited by 24
Treating the depressions with superficial brain stimulation methods
George, M. S., Taylor, J. J., & Short, B. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53497-2.00033-4 · Cited by 22
Predicting relapse in major depression after successful initial pharmacological treatment
Akechi, T., Mantani, A., Kurata, K., Hirota, S., Shimodera, S., Yamada, M., Inagaki, M., Watanabe, N., Kato, T., & Furukawa, T. A. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.004 · Cited by 26
Chen, S., Conwell, Y., Xu, B., Chiu, H. F. K., Tu, X. M., & Ma, Y. (2011) · Trials · doi:10.1186/1745-6215-12-121 · Cited by 24
“After unsuccessful treatment with an initial SSRI, bupropion provides a reasonable second-step choice for patients with depression [61].”
BackgroundQuest for Timely Detection and Treatment of Women With Depression
Alexander, J. L. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-a.3 · Cited by 24
Effectiveness as an outcome measure for treatment trials in psychiatry
Fleischhacker, W. W., & Goodwin, G. M. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00200.x · Cited by 21
“About 30% of patients in all groups treated with medication remitted after change in treatment, whatever the type (22,23).”
BackgroundSoares, C. N., Thase, M. E., Clayton, A. H., Guico‐Pabia, C. J., Focht, K., Jiang, Q. L., Kornstein, S. G., Ninan, P. T., & Kane, C. P. (2011) · CNS Drugs · doi:10.2165/11586460-000000000-00000 · Cited by 20
“Similar findings have been reported from other clinical trials evaluating the effectiveness of switching to a different antidepressant in patients who had not benefited from previous antidepressant therapy.([25-28]) Desvenlafaxine was generally safe and well tolerated during the study.”
ResultSelf-citationThe Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
Cipriani, A., Girlanda, F., Agrimi, E., Barichello, A., Beneduce, R., Bighelli, I., Bisoffi, G., Bisogno, A., Bortolaso, P., Boso, M., et al. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-212 · Cited by 22
“(QIDS) [20], a self-rated instruments that has been shown to have good psychometric properties [21].”
BackgroundAssessing anxious features in depressed outpatients
McClintock, S. M., Husain, M. M., Bernstein, I. H., Wisniewski, S. R., Trivedi, M. H., Morris, D., Alpert, J., Warden, D., Luther, J. F., Kornstein, S. G., et al. (2011) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.353 · Cited by 20
Self-citationAhmed, A. T., Biernacka, J. M., Jenkins, G. D., Rush, A. J., Shinozaki, G., Veldić, M., Kung, S., Bobo, W. V., Hall‐Flavin, D. K., Weinshilboum, R. M., et al. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.021 · Cited by 23
“This study utilized data from two clinical trials (Mrazek et al., 2014; Rush et al., 2006) of SNRIs in patients with MDD who had previously failed prospective treatment with an SSRI.”
MethodResultSelf-citation
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.